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Companion diagnostics are an emerging and exciting ﬁeld in the care of oncology patients. These tests accompany standard
diagnostic investigations in cancer patients and function as an aid in treatment decision making. A great number of new
compounds are under clinical and laboratory testing in nonsmall cell lung cancer (NSCLC). As the variety of therapeutic options
expands in the various settings of the disease, it becomes apparent that speciﬁc and sensitive molecular tests are necessary to
deﬁne the subsets of patients who are going to derive clinical beneﬁt. Testing for epidermal growth factor receptor (EGFR) somatic
mutations for the appropriate administration of tyrosine kinase inhibitors is just the beginning. Anaplastic lymphoma kinase
(ALK) fusion protein detection and molecular histology classiﬁcation are promising candidate predictors for clinical beneﬁt from
crizotinib and pemetrexed, respectively. This paper summarizes such diagnostics and discusses unanswered questions concerning
underlying biology and standardization issues.
1.Introduction
Nonsmall cell lung cancer (NSCLC) is the leading cause
of cancer-related death worldwide [1]. Adenocarcinoma,
squamous cell, and large cell carcinoma are the major
histologic types. The majority of patients are diagnosed with
metastatic disease and their treatment options are limited
to systemically administered modalities often at the cost of
signiﬁcant adverse events. With regard to clinical beneﬁt
to toxicity ratio, tailoring treatment to every patient with
NSCLC has emerged as a long-term goal. Recent advances in
understanding tumor biology have provided new treatment
targets as well as exciting insights into designing treatment
plans according to unique molecular proﬁles.
Companion diagnostics are tests that accompany diag-
nostic investigations in cancer patients and determine
whether speciﬁc drugs should, or should not, be admin-
istered. The history of such tests can be traced back to
the estrogen receptor in breast cancer: patients with this
disease beneﬁt from antiestrogen treatment if their tumors
express the receptor [2, 3]. In addition, patients with
breast cancer receive trastuzumab if their tumors express
HER2, a transmembrane receptor of the HER family [4].
Other examples include testing for KRAS mutations before
prescribing cetuximab treatment in colorectal cancers [5]
and testing for the presence of the Philadelphia chromosome
for imatinib treatment in chronic and refractory or relapsed
acute myeloid leukemias (AMLs) [6]. A companion diagnos-
tic test should be highly reproducible and accurate, as well
as rigorously standardized and validated before, it is widely
recommended for clinical application.
This paper summarizes recent progress in companion
diagnostics in NSCLC. In particular, testing for epidermal
growth factor receptor (EGFR) mutations and for anaplastic
lymphoma kinase (ALK) fusion proteins is discussed. Those
genetic alterations have been linked to response to tyrosine2 Pathology Research International
kinase inhibitors (TKIs) and ALK inhibitors, respectively.
Furthermore, we comment on assays for accurate and spe-
ciﬁc histologic classiﬁcation of NSCLC which are necessary
for appropriate use of pemetrexed and bevacizumab treat-
ment.
2.EGFR
EGFR is a transmembrane receptor present in the majority
of patients with NSCLC [7]. The receptor mediates cellular
response to various extracellular signals. It is encoded by the
proto-oncogene EGFR and demonstrates diverse function in
the biology of NSCLC.
EGFR activates two major downstream pathways, medi-
atedbyKirstenratsarcoma(KRAS)andphosphatidylinositol
3-kinase(PI3K)proteins,respectively.KRASisaproteinwith
GTPaseactivitywhichactivatesBRAFandﬁnallyERKaspart
of the mitogen-activated protein kinase (MAPK) signaling
cascade. On the other hand, PI3K activates phospholipase C
(PLC), protein kinase beta (PKB/AKT), and the mammalian
target of rapamycin (mTOR) complex. A set of interactions
between these two pathways, as well as positive and negative
feedback loops, compose a complicated network which
mediates the impact of EGFR and other transmembrane
receptorsoncellproliferation,inhibitionofapoptosis,tumor
growth, and invasiveness.
2.1. EGFR Mutations. The receptor carries activating muta-
tions in its tyrosine kinase (exons 18–21) domain in a
subsetoftheNSCLCpopulation[8–10].Patientswithcertain
epidemiologic characteristics (adenocarcinoma histology,
never smoking status, female gender, and Asian ethnicity)
are more likely to harbor the mutations [8–10]. Most of
the mutations are in frame deletions in exon 19 and a
point mutation in exon 21 (L858R) [11]. A deletion between
codons 746 and 750 accounts for 65–75.5% of the deletions
in exon 19 [12].
Erlotinib and geﬁtinib are compounds that reversibly
inhibit the tyrosine kinase activity of EGFR and have been
employed in the treatment of patients with NSCLC. Clinical
beneﬁt is modest in the unselected population with the
disease [13]. However, tumors which harbor activating
mutations of the tyrosine kinase domain of EGFR tend to
respond to TKIs [8–10]. Patients with the mutations have a
prolonged time to progression when treated with geﬁtinib
as a ﬁrst-line regimen compared to chemotherapy, whereas
the opposite is true at the absence of a mutation [14–16].
The results of such clinical trials led to the consensus that an
eﬀortshouldbemadetodeﬁnethemutationalstatusinevery
newly diagnosed patient with NSCLC in order to decide
appropriately on the use of TKIs in the ﬁrst-line setting [17].
2.1.1. Consensus on EGFR Mutations Testing. The recent
clinical trials that have established TKIs treatment in the
ﬁrst-line setting for NSCLC patients with activating EGFR
mutations have employed a variety of methods for mutation
detection (Table 1). Furthermore, a number of diﬀerent
methods have been described in other studies outside the
Table 1: Diﬀerent assays for detection of EGFR mutation that have
been used before TKI treatment in phase III trials in the ﬁrst-line
setting.
Study Assay
Maemondo
et al. [15]
Peptide nucleic acid-locked nucleic acid
PCR clamp
Mitsudomi
et al. [16]
Fragment analysis, Cycleave method, direct
sequencing, peptide nucleic acid-locked
nucleic acid PCR, PCR invader
Mok et al. [14] Ampliﬁcation refractory mutation system
(ARMS)
context of clinical trials [18, 19]. Each of these methods has
been validated by comparison to direct sequencing in order
to estimate its sensitivity and speciﬁcity. However, many of
the validation studies have been performed in small cohorts
and by a limited number of research groups for each method
[20–22]. Taken together, the lack of a common protocol for
testing tumors for EGFR mutations and the need for more
solid validation of such protocols and procedures in large
studies by independent groups indicate the type of studies
that will support a consensus on testing for the presence of
EGFR mutations.
T h em o s tc o m m o n l yu s e dm u t a t i o nd e t e c t i o nm e t h o di s
direct DNA sequencing following extraction of DNA from a
tumor sample. DNA sequencing is, however, a challenging
task when a small biopsy or even a cytology block is the
onlysampleavailableforcompaniondiagnostics.Thisisvery
often the case in the metastatic setting for NSCLC patients.
Another limitation is that genotyping methods based on
DNA extraction are subject to sample contamination with
non-tumor DNA derived from normal or stromal cells.
When the percentage of non-tumor to tumor DNA exceeds
a certain threshold, it is likely that a mutation might not
be detected by direct sequencing as the mutation-speciﬁc
signal will not surpass the background. Other methods have
been developed and reported to have superior sensitivities
[23–25]. In addition, the number of malignant cells that
need to be present in a sample and the number of diﬀerent
cores or blocks that need to be tested before providing a
reliable result on EGFR mutation status are not known. It
is largely dependent on the heterogeneity of mutated EGFR
expression within a core, across diﬀerent cores and diﬀerent
tissue blocks. Although EGFR mutations occur early in
the tumorigenesis process and one would, therefore, expect
them to be homogeneous, tumor heterogeneity of EGFR
mutations has not been assessed thoroughly so far. In fact, it
has been reported that there is discrepancy in the mutational
status between the primary tumors and their metastases
[26, 27], as well as a level of heterogeneity within a tissue
block [28, 29]. Thus, it is imperative to determine the level
of heterogeneity of mutated EGFR in order to propose a
standard protocol for reliable mutation detection.
Besides genotyping, immunohistochemistry (IHC) has
become available for the most common mutations [19].
Antibodies have been designed to detect speciﬁcally in frame
deletions in exon 19 and point mutations in exon 21. DespitePathology Research International 3
the high sensitivity and speciﬁcity that was initially reported
[12, 19], subsequent studies have shown that the “mutation-
speciﬁc” antibodies are able to detect only 80% of the full
spectrum of mutations [30, 31]. Kitamura et al. [29]h a v e
reported sensitivity as low as 47%, probably because of the
high frequency of uncommon mutations in their cohort.
Most of the studies, however, conclude that deletion-speciﬁc
antibody methodology is ineﬃcient at detecting deletions in
exon 19 other than the “classic” in frame deletion between
codons 746 and 750. On the other hand, IHC is available
in most pathology laboratories and it is more clinically
relevant than genotyping as it assesses mutations at the
proteinlevelwhereaTKI’sfunctionoccurs.Besides,theassay
is highly speciﬁc and can be used as an initial assessment
before conﬁrmatory genotyping is performed. While still
experimental, this in situ method may become a useful
research tool in illuminating topics such as the heterogeneity
of mutant EGFR and the dynamic range of mutant EGFR
expression.
2.1.2. Prediction of Secondary Resistance to TKIs. Even when
an EGFR-mutated tumor is initially controlled with EGFR
inhibition, resistance emerges typically after a median of
9–12 months [14–16]. Diﬀerent mechanisms of acquired
resistance have been described. About half of the cases
become resistant because of a point mutation (T790M)
in exon 20 [32, 33] and 20% of the cases because of
ampliﬁcation of hepatocyte growth factor receptor (MET)
[34]. MET is a transmembrane receptor which can activate
EGFR downstream targets via a parallel pathway. Both
resistance mechanisms are present in 10% of the patients
who become refractory to tyrosine kinase inhibition after
initial response [35]. There is evidence to suggest that both
MET ampliﬁcation and T790M point mutation might be
presentinalownumberoftumorcellsbeforeadministration
of tyrosine kinase inhibitor treatment. These cells are
selectively enriched after EGFR inhibition [36, 37]. Recently,
it was shown that resistance can emerge as the result of
activation of a loop between TGF beta and IL6 [38], or
through derepression of FGFR2 and FGFR3 [39]o re v e n
through phosphatase and tensin homolog (PTEN) loss [40].
These three additional modes of acquired resistance have
not yet been validated in large cohorts of patients and their
importance remains to be determined. Taken together, these
data strongly support the notion that patients should be
tested for the presence of genetic alterations that might cause
resistance after failure of TKIs and treated appropriately
on the basis of such diagnostics. There are currently drugs
that can overcome T790M-mediated resistance as shown in
preclinical reports [41]. Eﬃcient MET inhibitors become
relevant in cases of MET ampliﬁcation [42]. Some of these
regimens are being tested in ongoing clinical trials. Whether
the employment of such modalities should follow the failure
of TKIs or, alternatively, should accompany TKIs in the ﬁrst-
line setting in order to prevent the emergence of resistance
remains an open question.
2.2. Miscellaneous Mutations in the EGFR Pathway. An u m -
ber of activating mutations have been described in the
component molecules of this network among patients with
NSCLC. Mutations in KRAS [43] are the most well studied.
KRAS mutations cause primary resistance of the tumors to
TKIs [43]. However, they are mutually exclusive to EGFR
mutations [44] and, at the same time, they are not always
present in patients who are resistant to TKIs. Thus, detection
of such mutations is inferior to EGFR mutation detection
and is not currently recommended as a diagnostic test before
EGFR inhibition. In some centers, a strategy of “reﬂex”
testing is followed: patients with adenocarcinoma are tested
for the presence of EGFR mutations ﬁrst and, if negative,
theyaretestedforthepresenceofKRASmutations [45]inan
eﬀort to obtain information about the driver mutation while
saving time, tissue, and resources.
Additional mutations have been identiﬁed in numerous
other genes [46]. HER2 [47], BRAF [48], and PI3K [49]
mutations are found in fewer than 5% of patients [44, 50]. In
contrast to KRAS mutations, PI3K mutations can be found
in both EGFR mutant or wild-type tumors and, therefore,
they might be responsible for primary resistance to TKIs
in patients with activating EGFR mutations. However, they
are rather rare and their predictive potential has yet to be
determined in the clinical setting. As several molecules of the
KRAS and PI3K pathways are targets of speciﬁc inhibitors
tested in ongoing clinical trials, such mutations are likely
to become clinically relevant in the future. A convenient
assay that combines a multiplex PCR step with a single-
base extension sequencing step can reliably test for many
diﬀerent mutations simultaneously and is already employed
by some centers [51]. The separation and identiﬁcation of
the diﬀerent alleles in this assay is performed on the basis
of diﬀerent ﬂuorescence colors and diﬀerent sizes of allele-
speciﬁc probes.
Figure 1 summarizes the spectrum of histotype classiﬁ-
cation for NSCLC and the frequency of diﬀerent mutations
in the two major histotypes. It becomes apparent that the
“NSCLC puzzle” has yet to become completed, especially in
squamous cell carcinomas. Besides, unraveling the puzzle of
genetic alterations, certain treatment strategies are needed in
conjunction to novel diagnostics.
Since the spectrum of mutations is unique to each
histologic type, as shown in Figure 1, it becomes apparent
t h a tt u m o r so fd i ﬀerent histology are expected to behave
diﬀerently after exposure to treatments that target speciﬁc
genetic alterations. In this regard, tyrosine kinase inhibitors
are more clinically relevant for the treatment of patients with
adenocarcinoma. Likewise, antiangiogenic compounds, like
bevacizumab, are contraindicated in patients with squamous
cell carcinoma as they might cause lethal bleeding in those
patients.
3. AnaplasticLymphoma Kinase(ALK)
Progress in the understanding of EGFR mutations revealed
that some tumors rely on single driving genetic alterations,
a phenomenon better known as oncogene addiction. The
discovery of an “Achilles’ heel” in a small subset of the
NSCLC population has led to the exciting perspective of
exploring novel pathways that are vital to cancer existence4 Pathology Research International
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Figure 1: Summary of histotype classiﬁcation in NSCLC according to the California Cancer Registry [52] and the patterns of mutations
seen in squamous cell carcinomas and adenocarcinomas [12, 19, 43, 47, 48, 50].
and which can potentially be switched oﬀ with modern
treatment strategies. Reporting of ALK activation in some
patients with NSCLC is part of this perspective.
ALK is a transmembrane receptor with tyrosine kinase
activity that belongs to the insulin growth factor receptor
family, encoded on chromosome 2 (2p23). When bound to
its ligand or otherwise activated, it transmits antiapoptotic
and cell proliferation signals mediated by KRAS and PI3K
pathways [53, 54]. Aberrant activation of ALK was ﬁrst
described in anaplastic large cell lymphoma (ACLC) [54]
and in inﬂammatory myoﬁbroblastic tumor (IMT) [55].
ALK contributes to NSCLC biology after being fused with
a number of other genes and most frequently Echinoderm
microtubule-associated protein 4 (EML4)[ 56, 57]. EML4
gene is located on chromosome 2 (2p21) and is reversely
oriented with ALK. EML4-ALK fusion might occur after a
cleavage of the chromosome at a variable site and chromo-
some inversion, giving rise to diﬀerent fusion isoforms [58].
EML4-ALK fusion occurs in a mutually exclusive fashion
with EGFR or KRAS mutations and, almost exclusively,
in adenocarcinomas [59]. However, there have been rare
reports of co-existence of EML4-ALK and EGFR mutations
[60] or squamous cell carcinoma histology [61]. The pres-
ence of EML4-ALK is more likely in patients with certain
demographic characteristics, such as never smoking status
or younger age [59]. Although a frequency range of 0.4–
13.5% [62] has been reported, most studies discover this
genetic abnormality at a rate of 2–5% [62–64] in the general
population of patients with NSCLC.
3.1. Targeting ALK in NSCLC. Tumors that harbor an
activated ALK are addicted to the ALK pathway. On the
other hand, it appears that these tumors do not respond to
EGFR inhibition. Soda et al. showed the oncogenic potential
of EML4-ALK in a transgenic mouse model and proved the
dependence of the EML4-ALK-positive tumors on the fusion
protein [65]. Crizotinib is a dual MET and ALK inhibitor
which was already being tested in a clinical trial as a MET
inhibitoratthetimeofALKdiscovery.InaphaseIItrialin82
patients with activated ALK, crizotinib had a response rate of
57%[66].ArandomizedphaseIIIclinicaltrialinthesecond-
line setting of NSCLC is already recruiting patients with ALK
fusiongene.GiventhehighlypromisingphaseIIearlyresults,
it is likely that testing for the presence of ALK fusion protein
will emerge as a diagnostic guide for ALK inhibition. Thus,
standardization of this test is an important goal.
3.2. Testing for ALK Fusion Gene. An u m b e ro fd i ﬀerent
assays have been used for the detection of ALK fusion in
NSCLC. Fluorescent in situ hybridization (FISH) can be
used either as a “fusion” or as a “split-signal” assay [67].
In the fusion variant, diﬀerent color ﬂuorescence is used
for EML4 and for ALK. When a fusion is present, a third
color emerges from the overlay. In the split-signal variant,
an ALK break-apart probe with diﬀerent colors (green and
red) for the telomeric and the centromeric end of the
gene is used. When a fusion is present, 5 and 3 probes
are split, or an isolated 3 probe is detected. In the wild-
type cells, a merge/yellow signal is obtained. With either
variant, a tumor sample is considered to be positive when
more than 15% of the tumor cells are positive for the ALK
fusion gene. Those techniques have proved feasible in a
variety of tumor samples like formalin-ﬁxed and paraﬃn-
embedded (FFPE) tissue, pleural eﬀusions, sputum, and
small biopsies. FISH has a number of limitations. It requires
a level of expertise which is not widely spread in pathologyPathology Research International 5
laboratories. In addition, a positive signal (especially with
the most widely used split-signal assay) is often subtle and
easily missed. Furthermore, a distinction between neoplastic
and nonneoplastic cells can be diﬃcult in the absence
of direct histological/immunohistochemical correlation on
contiguous slides. Finally, the threshold of 15% is rather
arbitrary; indeed, it is not followed in all studies [64].
Reverse transcriptase-polymerase chain reaction (RT-
PCR) is another way to look for the fusion protein. Primers
that generate an amplicon only when a fusion is present are
used [56]. An additional step of sequencing can be added for
further validation of the result. A limitation to this assay is
that RNA is often degraded in FFPE tissue.
A third option is to look for the fusion at the protein
level, which is a goal of high clinical relevance since ALK
inhibitorsaretargetingproteinsratherthangenes.IHCoﬀers
in situ information about protein expression and allows
correlation with tumor morphology. Besides, it is widely
available because of its low cost and simplicity. A number
of diﬀerent antibody clones for ALK detection have been
described so far [68–70]. It appears that ALK1 clone lacks
sensitivity due to cases with high background whereas D5F3
clone has a more preferable signal-to-background ratio [69].
Interestingly, Mino-Kenudson et al. propose an objective,
quantitative, and automated assay for ALK detection [69].
Subjectivity in IHC interpretation and positivity threshold
detection, as well as insuﬃcient antibody validation, are
known limitations of IHC [71, 72].
Martelli et al. [68] reported the presence of EML4-ALK
fusion transcripts detected with RT-PCR in normal lung
tissue from NSCLC whose tumors were negative for such
transcripts. In addition, they failed to detect any protein in
IHC, probably because protein levels were too low to be
detected. Interestingly, ALK1 along with other clones was
usedforthedetectionofthefusionproteinsinIHC.Camidge
et al. [73] have discovered ALK fusion genes by FISH
in normal lung adjacent to ALK-positive or ALK-negative
lung tumors. Taken together, these studies underscore the
importance of further research in the biology of ALK protein
in lung tumors; the possible presence of ALK fusion genes in
normallung might drive thespectrumof adverseeventsfrom
treatment with crizotinib.
4.Assaysfor Histologic
Classiﬁcationof NSCLC
Histological classiﬁcation of NSCLC has been reviewed and
changed several times in the past decades according to
emerging knowledge on the disease. However, the need
for speciﬁc diagnosis of adenocarcinoma or squamous cell
carcinoma, the two major types of NSCLC has become
clinically relevant only recently.
Current NSCLC treatment optimization is histology
speciﬁc. In this context, pemetrexed (thymidylate synthase
inhibitor) and bevacizumab (anti-angiogenesis monoclonal
antibody) are approved for the treatment of non-squamous
cell lung carcinomas [74–76]. Histology classiﬁcation is
traditionally based on morphological criteria. Morphology
was able to classify correctly only 54% of preoperative
cytological and tissue samples [77]. Ou and Zell showed
that the percentage of patients diagnosed with NSCLC and
classiﬁed as “Not Otherwise Speciﬁed” (NOS) was much
greater when a cytology specimen was used for diagnosis
(39% versus 22.1% overall) in the California Cancer Registry
[52]. NOS is a diagnosis that should be strictly limited to
small biopsies and cytology specimens [78]. Histological
misclassiﬁcation can happen as pathologists agreed with
each other in 71.5% of the cases in a study [79]. The
adenocarcinoma-speciﬁc agreement rate was 82.9% and the
squamous-speciﬁc agreement rate was 91.2%.
4.1. Immunohistochemistry as an Aid for Histology Classiﬁca-
tion. Several markers have been shown to be diﬀerentially
expressed in adenocarcinomas and squamous cell carcino-
mas of the lung. Among them, mucin and thyroid transcrip-
tion factor 1 (TTF1) are adenocarcinoma-speciﬁc proteins,
whereas p63 and cytokeratins 5/6 (CK 5/6) are squamous
cell carcinoma speciﬁc. These markers were applied in a
panel of biopsy samples which were classiﬁed as NOS by
morphological criteria, and theassaywasableto classify73%
of the cases into a histological type. Further comparison with
matched surgical resections revealed accuracy of 86% [80].
Since none of these proteins is deﬁnitive when tested as a
single marker, a combination of them creates patterns that
favor speciﬁc histological types. Furthermore, a quantitative
approach that is based on a weighted algorithm of the
expression of ﬁve proteins is better at classifying NSCLC
NOS into squamous cell carcinoma or adenocarcinoma
than TTF1/TP63 staining [81]. Taken together, these studies
underscore the value of IHC as a diagnostic that aids correct
histological classiﬁcation and, therefore, the optimization of
treatment in NSCLC.
4.2. Micro-RNA 205. For the subset of cases which remain
unclassiﬁedaftermorphologicalcriteriaandIHCdiagnostics
have been applied, more sophisticated tests are emerging.
Micro-RNA 205 is a small RNA molecule that is expressed
in squamous cell carcinomas of the lung but not in lung
adenocarcinomas. A diagnostic test based on the expression
of micro-RNA 205, micro-RNA 21, and snRNA U6 can
predict squamous cell carcinoma with a sensitivity of 96%
and a speciﬁcity of 90% [82]. These ﬁndings were validated
from a separate study where the micro-RNA-205-based
diagnostic was able to predict histology perfectly in a
set of poorly diﬀerentiated squamous cell carcinomas and
adenocarcinomas [83]. In the same study, the diagnostic
was able to predict correctly histology in 20 out of 21
prospectively collected biopsies with matched resections. A
possible limitation of the assay is that it requires a tumor
cellularity of at least 50% in the block. Indeed, micro-RNA
205 expression can be artiﬁcially altered by contamination
from stromal or normal cells. It would be interesting to
see whether assessment of micro-RNA 205 with an in situ
assay like in situ hybridization (ISH) with micro-RNA-
speciﬁc probes can overcome this limitation. It is unknown
whether diﬃcult cases that need the aid of sophisticated and
expensive tests to be classiﬁed correctly respond the same
to pemetrexed as clear-cut cases. In this regard, it would6 Pathology Research International
be interesting to test whether micro-RNA 205 can predict
beneﬁt to those drugs as a companion diagnostic superior
to histological type.
5. Concluding Remarks
At the dawn of companion diagnostics in NSCLC, a number
of diﬀerent tests establish the role of the pathologist as
the prescribing physician. Indeed, such tests guide clinical
decisions in a similar fashion to trastuzumab administration
on the basis of HER2 positivity or antiestrogen treatment
on the basis of estrogen receptor positivity in breast cancer.
As more and more tests will be required in every newly
diagnosed patient, standardization of the assays as well as
further clariﬁcation of the biology of the candidate markers,
becomes increasingly relevant as legitimate goals in both
research and clinical practice. Last, but not least, laboratories
that perform these tests should be certiﬁed by national or
global institutions like Clinical Laboratory Improvement
Amendments (CLIA).
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